Conclusion
This study provides data in a critically ill patient population, all of whom received IV insulin, and demonstrates significant reduction in POC testing, a fair degree of sensor accuracy and maintained patient safety. Although it would be of interest to formally compare various hybrid approaches, our data suggest that more liberal criteria can be applied to a hybrid protocol, including earlier use as soon as CGM validation is achieved, reduced frequency of POC BG monitoring, and nonadjunctive use (eg, for dose titration). A prospective multicenter study in a more diverse population of critically ill patients is needed.
Acknowledgments
The authors thank the medical intensive care unit nursing staff at The Ohio State University Medical Center. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Funding
None.
Additional Information
Data Availability
Restrictions apply to the availability of some or all data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.
J Clin Endocrinol Metab. 2021;106(10):e4007-e4016. © 2021 Endocrine Society
